Literature DB >> 16785260

Metformin treatment is effective in obese teenage girls with PCOS.

Vincenzo De Leo1, M C Musacchio, G Morgante, P Piomboni, F Petraglia.   

Abstract

BACKGROUND: Polycystic ovary syndrome (PCOS) is the most frequent cause of menstrual disorders in teenage girls. Little information is available about the effects of metformin in adolescent girls with PCOS and its dose and its efficacy in regulating menstrual cyclicity and hyperandrogenic symptoms. We evaluated the effects of metformin treatment on ovulatory function, hirsutism, acne, hormonal patterns and body weight in adolescent girls with PCOS.
METHODS: Eighteen girls, ranging in age from 15 to 18 years, were enrolled in the study. Clinical diagnosis of PCOS was based on the consensus criteria for PCOS accepted in May 2003 at Rotterdam. All subjects received 1700 mg/day metformin as tablets continuously for 6 months. They were then followed up for 6 months.
RESULTS: Two patients complained of side effects for >2 weeks and interrupted treatment; they were not evaluated. All the others showed an improvement in menstrual cyclicity. Menstrual periods were ovulatory, with progesterone levels up to 6 ng/ml in luteal phase and a significant reduction in testosterone, androstenedione and free testosterone. BMI was restored within normal limits in all girls between 21 and 24 kg/m(2). Six months after the end of metformin treatment, menstrual cycles continued to be regular and ovulatory with normal BMI. Side effects were slight.
CONCLUSIONS: The present results confirm the positive effects of metformin on menstrual periods and show that the drug can be administered to young women to improve ovulation and hyperandrogenic symptoms such as hirsutism, acne and weight gain.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16785260     DOI: 10.1093/humrep/del185

Source DB:  PubMed          Journal:  Hum Reprod        ISSN: 0268-1161            Impact factor:   6.918


  24 in total

Review 1.  PCOS in adolescence and type 2 diabetes.

Authors:  Anne-Marie Carreau; Jean-Patrice Baillargeon
Journal:  Curr Diab Rep       Date:  2015-01       Impact factor: 4.810

2.  Interventional studies for polycystic ovarian syndrome in children and adolescents.

Authors:  Patricia Myriam Vuguin
Journal:  Ped Health       Date:  2010-02

3.  [In Process Citation]

Authors:  Jonette E Keri; Adena E Rosenblatt
Journal:  J Clin Aesthet Dermatol       Date:  2008-09

4.  Sex hormone-binding globulin, oligomenorrhea, polycystic ovary syndrome, and childhood insulin at age 14 years predict metabolic syndrome and class III obesity at age 24 years.

Authors:  Charles J Glueck; John A Morrison; Stephen Daniels; Ping Wang; Davis Stroop
Journal:  J Pediatr       Date:  2011-03-01       Impact factor: 4.406

Review 5.  Diagnosis and challenges of polycystic ovary syndrome in adolescence.

Authors:  Sophia E Agapova; Tamara Cameo; Aviva B Sopher; Sharon E Oberfield
Journal:  Semin Reprod Med       Date:  2014-04-08       Impact factor: 1.303

Review 6.  Childhood obesity and its impact on the development of adolescent PCOS.

Authors:  Amy D Anderson; Christine M Burt Solorzano; Christopher R McCartney
Journal:  Semin Reprod Med       Date:  2014-04-08       Impact factor: 1.303

7.  Assessing and treating insulin resistance in women with polycystic ovarian syndrome.

Authors:  Michael L Traub
Journal:  World J Diabetes       Date:  2011-03-15

Review 8.  Polycystic ovary syndrome in the pediatric population.

Authors:  Andrew A Bremer
Journal:  Metab Syndr Relat Disord       Date:  2010-10       Impact factor: 1.894

9.  Impact of metformin monotherapy versus metformin with oestrogen-progesterone on lipids in adolescent girls with polycystic ovarian syndrome.

Authors:  Miriam A Bredella; Shilpa McManus; Madhusmita Misra
Journal:  Clin Endocrinol (Oxf)       Date:  2013-04-01       Impact factor: 3.478

Review 10.  Effectiveness of myoinositol for polycystic ovary syndrome: a systematic review and meta-analysis.

Authors:  Liuting Zeng; Kailin Yang
Journal:  Endocrine       Date:  2017-10-19       Impact factor: 3.633

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.